|
|||||
|
|
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized,double‐blind,placebo‐controlled trial |
|
| Authors: | R. E. Ratner J. Rosenstock G. Boka |
| Affiliation: | 1. Medstar Research Institute and Georgetown University Medical School, Washington, DC, USA;2. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA;3. sanofi‐aventis R&D, Chilly‐Mazarin cedex, France |
| Abstract: | |
| Keywords: | glucagon‐like peptide‐1 receptor agonist glycaemic control lixisenatide Type 2 diabetes |